Susanne Tilk

@SusanneTilk

Biology PhD candidate studying somatic evolution in cancer.

Vrijeme pridruživanja: siječanj 2018.

Tweetovi

Blokirali ste korisnika/cu @SusanneTilk

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @SusanneTilk

  1. Prikvačeni tweet
    16. ruj 2019.

    Really excited to share the first chapter of my PhD on how genome-wide linkage in cancer reduces the efficacy of selection via Hill-Robertson interference (HRI), with mentors , and . (1/10)

    Prikaži ovu nit
    Poništi
  2. proslijedio/la je Tweet
    30. sij

    Ever wonder which tumor suppressor alterations impact drug responses in vivo? Check out our recent work on using improved Tuba-seq to quantify genotype-specific treatment responses in lung cancer.

    Prikaži ovu nit
    Poništi
  3. proslijedio/la je Tweet
    3. pro 2019.

    Check out the paper on G3 by the amazing & and coauthors. 1/n

    Prikaži ovu nit
    Poništi
  4. proslijedio/la je Tweet
    13. stu 2019.

    My first study on somatic mutations in corals! We found heterogeneity among different branches of individual corals. This occurs at a similar frequency as has been reported in humans. Intriguingly, for corals the most common form of that heterogeneity is losses of heterozygosity.

    Prikaži ovu nit
    Poništi
  5. proslijedio/la je Tweet
    17. ruj 2019.

    I am extremely excited about this work on the way natural selection succeeds and crucially fails to weed out deleterious mutations in cancer due to the constraints posed by linkage and Hill-Robertson interference. 1/n

    Prikaži ovu nit
    Poništi
  6. 16. ruj 2019.

    How successful tumors overcome this deleterious load is an exciting, open question. Similar to constraints in germ-line evolution, we think that preventing protein mis-folding is an important first step. We’d love to hear what you think! (10/10)

    Prikaži ovu nit
    Poništi
  7. 16. ruj 2019.

    Thus, this allowed us to estimate that in elevated mutational burden tumors (>95% of cancers), deleterious passengers accumulate and confer an individually-weak, but collectively-substantial fitness cost of ~40% that impacts tumor progression. (9/10)

    Prikaži ovu nit
    Poništi
  8. 16. ruj 2019.

    Finally, we demonstrate that a simple evolutionary model incorporating HRI can explain these observed patterns of selection and allowed us to estimate the mean fitness effects of passengers (~1%) and drivers (~18%) – much larger than previously estimated. (8/10)

    Prikaži ovu nit
    Poništi
  9. 16. ruj 2019.

    Importantly, we see that attenuated selection on CNAs and SNVs is generic to tumor evolution. This pattern persists across broad and specific tumor sub-type categories. (7/10)

    Prikaži ovu nit
    Poništi
  10. 16. ruj 2019.

    We see the same trend in somatic CNAs. Using a dN/dS-style statistic called dE/dI (fractional overlap of CNAs in [E]xonic versus [I]ntergenic/[I]ntronic regions) – we similarly see that selection on CNAs attenuates as the mutational burden increases. (6/10)

    Prikaži ovu nit
    Poništi
  11. 16. ruj 2019.

    To test this idea, we calculated dN/dS in tumors stratified by their mutational burden and observe that negative and positive selection attenuates as more mutations accumulate in tumors. (5/10)

    Prikaži ovu nit
    Poništi
  12. 16. ruj 2019.

    Since linkage effects get stronger as mutation rates increase, tumors with elevated mutational burdens should be particularly inefficient at removing deleterious passengers due to genetic hitchhiking and Muller’s Ratchet. (4/10)

    Prikaži ovu nit
    Poništi
  13. 16. ruj 2019.

    We hypothesized that since tumors evolve asexually, under the constraints of genome-wide linkage, mutations are unable to be removed by negative selection (or favored by positive selection). (3/10)

    Prikaži ovu nit
    Poništi
  14. 16. ruj 2019.

    Here, we try to resolve why signals of negative selection are largely absent in cancer, yet pre-dominant in the human germ-line. (2/10)

    Prikaži ovu nit
    Poništi
  15. proslijedio/la je Tweet

    Today at petrov lab meeting we explored a very important question...which spicy Cheeto is spicier? We double blinded and controlled for Cheeto size but we’re still really confused about whos spicier. , can you help us out?

    Poništi
  16. proslijedio/la je Tweet
    8. velj 2019.

    Excited to share our new paper on clonal replacement and heterogeneity through neoadjuvant therapy in Her2+ breast cancer: . Great work from and Katherine McNamara and the rest of the team!

    Poništi
  17. proslijedio/la je Tweet
    14. pro 2018.

    We have a new paper on bioRxiv today. It’s not a paper I was planning to write during my first semester as a postdoc. (1/n)

    Prikaži ovu nit
    Poništi
  18. proslijedio/la je Tweet
    16. stu 2018.

    The Geiler-Samerotte lab is recruiting graduate students and postdocs! Graduate students apply here by December 1rst: Postdocs apply here:

    Poništi
  19. proslijedio/la je Tweet
    8. stu 2018.

    COLBERT (control of lineages by barcode enabled recombinant transcription) for cancer research!

    Poništi
  20. proslijedio/la je Tweet
    8. stu 2018.

    Christopher McFarland of talks about using TuBa-Seq + CRISPR/Cas9 + modeling to study genetic drivers of lung cancer evolution

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·